Skip to Content

CLL14 study five-year results: Significantly superior efficacy for Ven-Obi

Five-year results from the ongoing CLL14 study, comparing venetoclax-obinutuzumab (Ven-Obi) to chlorambucil-obinutuzumab (Clb-Obi) in patients with previously untreated chronic lymphocytic leukemia (CLL), continue to demonstrate superior efficacy with longer progression-free survival (PFS) in patients receiving Ven-Obi. Let the primary investigator Dr. Othman Al-Sawaf update you in this MEDtalk.

Othman Al-sawaf

Få adgang til artiklen

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top